Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ERIC 2022 | Identifying new CLL therapeutic targets by focusing on the evolution of cancer cells

Nicholas Chiorazzi • 7 Oct 2022
ERIC 2022
Chronic Lymphocytic Leukemia Leukemia

Nicholas Chiorazzi, MD, Feinstein Institute for Medical Research, Manhasset, NY, discusses how further understanding the basic biologic parameters of cancer cells could help identify novel therapeutic agents for chronic lymphocytic leukemia (CLL). Prof. Chiorazzi describes how leukemic B cells’ interactive abilities with other cells change as they mature, thus devising therapies that can target both immature and mature cells could be a future approach in the quest for new CLL agents. This interview took place at the 2022 European Research Initiative on CLL (ERIC) Meeting.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Nicholas Chiorazzi

2:49
Leukemic cell birth rate & the role of recently divided B cells in CLL
Nicholas Chiorazzi • 7 Oct 2022
1:02
Obstacles to achieving a cure in CLL
Nicholas Chiorazzi • 7 Oct 2022
3:56
Updates on cellular and molecular interactions in the CLL microenvironment
Nicholas Chiorazzi • 18 Sep 2021
4:25
The role of AID in CLL
Nicholas Chiorazzi • 18 Sep 2021

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals